**Supplementary Table 1: DOAC Concentration Ranges from Phase III trials**

**Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants, CNS Drugs**

Amichai Perlman, Rachel Goldstein, Lotan Choshen Cohen, Bruria Hirsh-Raccah, David Hakimian, Ilan Matok, Yosef Kalish, Daniel E. Singer, Mordechai Muszkat

| Indication | Apixaban | Rivaroxaban | Dabigatran |
|------------|-----------|-------------|------------|
| Stroke prevention in NVAF* | Treatment PE/VTE* | Stroke prevention in NVAF* | Treatment PE/VTE* | Prevention after hip surgery* | Stroke prevention in NVAF** | Treatment PE/VTE*** |
| Dose | 5 mg bid | 2.5 mg bid | 10 mg bid | 5 mg bid | 2.5 mg bid | 20 mg qd | 15 mg qd | 20 mg qd | 10 mg qd | 150 mg bid | 110 mg bid | 150 mg bid |
| Peak concentration (ng/mL) | 171 (91-321) | 123 (69-221) | 251 (111-572) | 132 (59-302) | 67 (30-153) | 249 (184-343) | 229 (178-313) | 270 (189-419) | 125 (91-196) | 184 (74-383) | 133 (52-275) | 175 (117-275) |
| References | [1–3] | [1] | [1] | [1,2] | [1] | [2–4] | [4] | [2,4] | [4] | [5] | [5] | [2] |

* Peak concentrations are listed as median (5th-95th percentile), ** listed as median (10th-90th percentile), *** listed as median (25th-75th percentile)

1. European Medicines Agency. Eliquis - EPAR Product Information. [Internet]. [cited 2020 Jun 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf

2. Gosselin R, Adcock D, Bates S, Douxfils J, Favaloro E, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118:437–50.

3. Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017;2:566.

4. Mueck W, Stampfuss J, Kubitz D, Becka M. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clin Pharmacokinet. 2014;53:1–16.

5. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. Journal of the American College of Cardiology. 2014;63:321–8.